Alnylam Pharmaceuticals, Inc ALNY

CAMBRIDGE, Mass., September 29, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of AMVUTTRA® (vutrisiran) ‘Play by Play,’ a U.S. educational initiative featuring former professional athletes living with the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) and the care teams who support them. Through personal stories and expert perspectives, ‘Play by Play’ aims to help people recognize the symptoms of ATTR-CM earl

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.

Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer (PFE) about 23%. The run's central event came on August 19, 2026, when Merck and Moderna said a Phase III trial of their cancer vaccine, intismeran autogene, met its endpoints in melanoma. A rough timetable for the trial was public long before the stock moved, but its result was not.

RNAi Therapeutics Expand on Precision Medicine Demand, Advanced Subcutaneous Delivery and Growing Rare Disease ApplicationsDublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "RNA Interference Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global RNA Interference Therapeutics Market to Reach USD 31.4 Billion by 2035 The global RNA interference therapeutics market was valued at USD 4.2 billion in 2025 a

Alnylam Pharmaceuticals recently presented at Wells Fargo’s 21st Annual Healthcare Conference in Boston and Morgan Stanley’s 24th Annual Global Healthcare Conference in New York, highlighting its RNA interference portfolio to investors and industry peers. These appearances coincided with a very large projected expansion of the global oligonucleotide therapeutics market to US$72.10 billions by 2035, underscoring Alnylam’s positioning as a key RNA-based medicines innovator. We’ll now examine...

By Karen Roman Slate Medicines Inc. said it appointed Kenneth Koblan, PhD, as its new Chief Scientific Officer, having previously served as Head of Research and Development at Vesalius Therapeutics, and at Sumitomo Pharma America as Chief Scientific Officer and Head of Development Operations. Dr. Koblan is a biopharmaceutical R&D leader with more than 30 years […] The post Slate Medicines Names Kenneth Koblan as Chief Scientific Officer appeared first on ExecEdge.

Oligonucleotide Therapeutics Expand Beyond Rare Diseases as RNA Innovation, Targeted Delivery and Patient-Friendly Dosing Accelerate AdoptionDublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Oligonucleotide Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Oligonucleotide Therapeutics Market to Reach USD 72.1 Billion by 2035 at a 23.4% CAGR The global oligonucleotide therapeutics market was valu

Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, September 18, 2026, the Index will be rebalanced, and the following changes will be effective.

American Century Investments, an investment management company, released its second-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]

170-Page Report Tracks Intellia and Regeneron's Nex-Z Through Phase III, Alnylam's Nucresiran Launch Plans, and the Full RNA-Silencing Competitive Landscape Reshaping hATTR TreatmentDublin, Sept. 04, 2026 (GLOBE NEWSWIRE) -- "Hereditary Transthyretin Amyloidosis - Market Insight, Epidemiology, and Market Forecast - 2036" report has been added to ResearchAndMarkets.com's offering.The report delivers an in-depth understanding of hATTR, its historical and forecasted epidemiology, and market trends

CAMBRIDGE, Mass., September 02, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: